Search

Your search keyword '"Joniau, S"' showing total 1,070 results
Start Over Author "Joniau, S" Language english
1,070 results on '"Joniau, S"'

1. Transcriptomic and clinical heterogeneity of metastatic disease timing within metastatic castration-sensitive prostate cancer

Author

Sutera, P.A., Shetty, A.C., Hakansson, A., Van der Eecken, K., Song, Y., Liu, Y., Chang, J., Fonteyne, V., Mendes, A.A., Lumen, N., Delrue, L., Verbeke, S., De Man, K., Rana, Z., Hodges, T., Hamid, A., Roberts, N., Song, D.Y., Pienta, K., Ross, A.E., Feng, F., Joniau, S., Spratt, D., Gillessen, S., Attard, G., James, N.D., Lotan, T., Davicioni, E., Sweeney, C., Tran, P.T., Deek, M.P., and Ost, P.

Published
2023
Full Text
View/download PDF

3. Risk factors for residual disease at re-TUR in a large cohort of T1G3 patients

Author

Pisano, F., Gontero, P., Sylvester, R., Joniau, S., Serretta, V., Larré, S., Di Stasi, S., van Rhijn, B., Witjes, A., Grotenhuis, A., Colombo, R., Briganti, A., Babjuk, M., Soukup, V., Malmstrom, P.U., Irani, J., Malats, N., Baniel, J., Mano, R., Cai, T., Cha, E., Ardelt, P., Varkarakis, J., Bartoletti, R., Dalbagni, G., Shariat, S.F., Xylinas, E., Karnes, R.J., and Palou, J.

Published
2021
Full Text
View/download PDF

6. Radical prostatectomy after vascular-targeted photodynamic therapy (VTP) with TOOKAD® : feasibility, early and intermediate results

Author

Pierrard, V., Lebdai, S., Kleinclauss, F., Azzouzi, A.-R., Terrier, J.E., Fortier, E., Joniau, S., Van Der Poel, H., Salomon, G., Casanova, J., Medina-Lopez, R.-A., Potiron, E., Rigaud, J., Vincendeau, S., Rassweiler, J., Villers, A., Gaston, R., Saussine, C., Giai, J., Gaillac, B., Emberton, M., and Ruffion, A.

Published
2018
Full Text
View/download PDF

7. Predictors of oncological outcomes in T1G3 patients treated with BCG who undergo radical cystectomy

Author

Soria, Francesco, Pisano, Francesca, Gontero, Paolo, Palou, J., Joniau, S., Serretta, V., Larré, S., Di Stasi, S., van Rhijn, B., Witjes, J. A., Grotenhuis, A., Colombo, R., Briganti, A., Babjuk, M., Soukup, V., Malmstrom, P. U., Irani, J., Malats, N., Baniel, J., Mano, R., Cai, T., Cha, E., Ardelt, P., Varkarakis, J., Bartoletti, R., Dalbagni, G., Shariat, S. F., Xylinas, E., Karnes, R. J., and Sylvester, R.

Published
2018
Full Text
View/download PDF

8. Recurrence, progression and cancer-specific mortality according to stage at re-TUR in T1G3 bladder cancer patients treated with BCG: not as bad as previously thought

Author

Palou, J., Pisano, F., Sylvester, R., Joniau, S., Serretta, V., Larré, S., Di Stasi, S., van Rhijn, B., Witjes, A. J., Grotenhuis, A., Colombo, R., Briganti, A., Babjuk, M., Soukup, V., Malmstrom, P. U., Irani, J., Malats, N., Baniel, J., Mano, R., Cai, T., Cha, E. K., Ardelt, P., Varkarakis, J., Bartoletti, R., Dalbagni, G., Shariat, S. F., Xylinas, E., Karnes, R. J., and Gontero, P.

Published
2018
Full Text
View/download PDF

9. The survival impact of neoadjuvant hormonal therapy before radical prostatectomy for treatment of high-risk prostate cancer

Author

Tosco, L, Laenen, A, Briganti, A, Gontero, P, Karnes, R J, Albersen, M, Bastian, P J, Chlosta, P, Claessens, F, Chun, F K, Everaerts, W, Gratzke, C, Graefen, M, Kneitz, B, Marchioro, G, Salas, R S, Tombal, B, Van den Broeck, T, Moris, L, Battaglia, A, van der Poel, H, Walz, J, Bossi, A, De Meerleer, G, Haustermans, K, Van Poppel, H, Spahn, M, and Joniau, S

Published
2017
Full Text
View/download PDF

14. Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project†

Author

Kramar, A., Negrier, S., Sylvester, R., Joniau, S., Mulders, P., Powles, T., Bex, A., Bonnetain, F., Bossi, A., Bracarda, S., Bukowski, R., Catto, J., Choueiri, T. K., Crabb, S., Eisen, T., El Demery, M., Fitzpatrick, J., Flamand, V., Goebell, P. J., Gravis, G., Houédé, N., Jacqmin, D., Kaplan, R., Malavaud, B., Massard, C., Melichar, B., Mourey, L., Nathan, P., Pasquier, D., Porta, C., Pouessel, D., Quinn, D., Ravaud, A., Rolland, F., Schmidinger, M., Tombal, B., Tosi, D., Vauleon, E., Volpe, A., Wolter, P., Escudier, B., Filleron, T., Kramar, Andrew, Sylvester, Richard, Filleron, Thomas, Negrier, Sylvie, Joniau, Steven, Mulders, Peter, Powles, Thomas, Escudier, Bernard, Bex, Axel, Bonnetain, Franck, Bossi, Alberto, Braccarda, Sergio, Bukowski, Ronald, Catto, James, Choueiri, Toni, Crabb, Simon, Eisen, Tim, El Demery, Mounira, Fitzpatrick, John, Flamand, Vincent, Goebell, Peter J., Gravis, Gwendael, Houédé, Nadine, Jacqmin, Didier, Kaplan, Richard, Malavaud, Bernard, Massard, Christophe, Melichar, Bohuslav, Mourey, Loïc, Nathan, Paul, Pasquier, David, Porta, Camillo, Pouessel, Damien, Quinn, David, Ravaud, Alain, Rolland, Frédéric, Schmidinger, Manuela, Tombal, Bertrand, Tosi, Diego, Vauleon, Elodie, Volpe, Alessandro, and Wolter, Pascal

Published
2015
Full Text
View/download PDF

16. O02 - Outcomes of Cytoreductive Radical Prostatectomy for Oligometastatic Prostate Cancer on PSMA-PET: Results of a Multicenter, European Study

Author

Rajwa, P., Robesti, D., Chaloupka, M., Zattoni, F., Giesen, A., Huebner, N.A., Krzywon, A., Miszczyk, M., Moll, M., Stando, R., Cisero, E., Semko, S., Checcucci, E., Devos, G., Apfelbeck, M., Gatti, C., Marra, G., van den Bergh, R.C.N., Goldner, G., Rasul, S., Ceci, F., Dal Moro, F., Porpiglia, F., Gontero, P., Bjartell, A., Stief, C., Heidenreich, A., Joniau, S., Briganti, A., Shariat, S.F., and Gandaglia, G.

Published
2023
Full Text
View/download PDF

33. Germline variation at 8q24 and prostate cancer risk in men of European ancestry (vol 9, 4616, 2018)

Author

Matejcic, M, Saunders, EJ, Dadaev, T, Brook, MN, Wang, K, Sheng, X, Al Olama, AA, Schumacher, FR, Ingles, SA, Govindasami, K, Benlloch, S, Berndt, SI, Albanes, D, Koutros, S, Muir, K, Stevens, VL, Gapstur, SM, Tangen, CM, Batra, J, Clements, J, Gronberg, H, Pashayan, N, Schleutker, J, Wolk, A, West, C, Mucci, L, Kraft, P, Cancel-Tassin, G, Sorensen, KD, Maehle, L, Grindedal, EM, Strom, SS, Neal, DE, Hamdy, FC, Donovan, JL, Travis, RC, Hamilton, RJ, Rosenstein, B, Lu, Y-J, Giles, GG, Kibel, AS, Vega, A, Bensen, JT, Kogevinas, M, Penney, KL, Park, JY, Stanford, JL, Cybulski, C, Nordestgaard, BG, Brenner, H, Maier, C, Kim, J, Teixeira, MR, Neuhausen, SL, De Ruyck, K, Razack, A, Newcomb, LF, Lessel, D, Kaneva, R, Usmani, N, Claessens, F, Townsend, PA, Gago-Dominguez, M, Roobol, MJ, Menegaux, F, Khaw, K-T, Cannon-Albright, LA, Pandha, H, Thibodeau, SN, Schaid, DJ, Wiklund, F, Chanock, SJ, Easton, DF, Eeles, RA, Kote-Jarai, Z, Conti, DV, Haiman, CA, Henderson, BE, Stern, MC, Thwaites, A, Guy, M, Whitmore, I, Morgan, A, Fisher, C, Hazel, S, Livni, N, Cook, M, Fachal, L, Weinstein, S, Freeman, LEB, Hoover, RN, Machiela, MJ, Lophatananon, A, Carter, BD, Goodman, P, Moya, L, Srinivasan, S, Kedda, M-A, Yeadon, T, Eckert, A, Eklund, M, Cavalli-Bjoerkman, C, Dunning, AM, Sipeky, C, Hakansson, N, Elliott, R, Ranu, H, Giovannucci, E, Turman, C, Hunter, DJ, Cussenot, O, Orntoft, TF, Lane, A, Lewis, SJ, Davis, M, Key, TJ, Brown, P, Kulkarni, GS, Zlotta, AR, Fleshner, NE, Finelli, A, Mao, X, Marzec, J, MacInnis, RJ, Milne, R, Hopper, JL, Aguado, M, Bustamante, M, Castano-Vinyals, G, Gracia-Lavedan, E, Cecchini, L, Stampfer, M, Ma, J, Sellers, TA, Geybels, MS, Park, H, Zachariah, B, Kolb, S, Wokolorczyk, D, Lubinski, J, Kluzniak, W, Nielsen, SF, Weisher, M, Cuk, K, Vogel, W, Luedeke, M, Logothetis, CJ, Paulo, P, Cardoso, M, Maia, S, Silva, MP, Steele, L, Ding, YC, De Meerleer, G, De Langhe, S, Thierens, H, Lim, J, Tan, MH, Ong, AT, Lin, DW, Kachakova, D, Mitkova, A, Mitev, V, Parliament, M, Jenster, G, Bangma, C, Schroder, FH, Truong, T, Koudou, YA, Michael, A, Kierzek, A, Karlsson, A, Broms, M, Wu, H, Aukim-Hastie, C, Tillmans, L, Riska, S, McDonnell, SK, Dearnaley, D, Spurdle, A, Gardiner, R, Hayes, V, Butler, L, Taylor, R, Papargiris, M, Saunders, P, Kujala, P, Talala, K, Taari, K, Bentzen, S, Hicks, B, Vogt, A, Hutchinson, A, Cox, A, George, A, Toi, A, Evans, A, Van der Kwast, TH, Imai, T, Saito, S, Zhao, S-C, Ren, G, Zhang, Y, Yu, Y, Wu, Y, Wu, J, Zhou, B, Pedersen, J, Lobato-Busto, R, Manuel Ruiz-Dominguez, J, Mengual, L, Alcaraz, A, Pow-Sang, J, Herkommer, K, Vlahova, A, Dikov, T, Christova, S, Carracedo, A, Tretarre, B, Rebillard, X, Mulot, C, Adolfsson, J, Stattin, P, Johansson, J-E, Martin, RM, Thompson, IM, Chambers, S, Aitken, J, Horvath, L, Haynes, A-M, Tilley, W, Risbridger, G, Aly, M, Nordstrom, T, Pharoah, P, Tammela, TLJ, Murtola, T, Auvinen, A, Burnet, N, Barnett, G, Andriole, G, Klim, A, Drake, BF, Borre, M, Kerns, S, Ostrer, H, Zhang, H-W, Cao, G, Lin, J, Ling, J, Li, M, Feng, N, Li, J, He, W, Guo, X, Sun, Z, Wang, G, Guo, J, Southey, MC, FitzGerald, LM, Marsden, G, Gomez-Caamano, A, Carballo, A, Peleteiro, P, Calvo, P, Szulkin, R, Llorca, J, Dierssen-Sotos, T, Gomez-Acebo, I, Lin, H-Y, Ostrander, EA, Bisbjerg, R, Klarskov, P, Roder, MA, Iversen, P, Holleczek, B, Stegmaier, C, Schnoeller, T, Bohnert, P, John, EM, Ost, P, Teo, S-H, Gamulin, M, Kulis, T, Kastelan, Z, Slavov, C, Popov, E, Van den Broeck, T, Joniau, S, Larkin, S, Esteban Castelao, J, Martinez, ME, Van Schaik, RHN, Xu, J, Lindstrom, S, Riboli, E, Berry, C, Siddiq, A, Canzian, F, Kolonel, LN, Le Marchand, L, Freedman, M, Cenee, S, Sanchez, M, and Commission of the European Communities

Subjects
Multidisciplinary Sciences, Science & Technology, MD Multidisciplinary, Science & Technology - Other Topics, PRACTICAL Consortium
Abstract

Correction to: Nature Communications; https://doi.org/10.1038/s41467-018-06863-1, published online 5 November 2018.

Published
2019

34. Assessment of the Safety of Glucocorticoid Regimens in Combination With Abiraterone Acetate: A Randomized, Open-Label Phase 2 Study

Author

Attard, G., Merseburger, A. S., Arlt, W., Sternberg, C. N., Feyerabend, S., Berruti, A., Joniau, S., Geczi, L., Lefresne, F., Lahaye, M., Shelby, F. N., Pissart, G., Chua, S., Jones, R. J., Tombal, B., UCL - SSS/IREC/CHEX - Pôle de chirgurgie expérimentale et transplantation, and UCL - (SLuc) Service d'urologie

Abstract

IMPORTANCE: Abiraterone acetate is combined with prednisone, 5 mg, twice daily for metastatic castration-resistant prostate cancer (mCRPC) and with prednisone, 5 mg, once daily for newly diagnosed, high-risk, metastatic castration-sensitive prostate cancer. Understanding the physiological effects of these and other regimens is important. OBJECTIVE: To evaluate the safety of abiraterone acetate with 4 glucocorticoid regimens. DESIGN, SETTING, AND PARTICIPANTS: Open-label, randomized clinical trial (1:1:1:1) of 164 men with mCRPC from 22 hospitals in 5 countries who were randomly assigned to 1 of 4 intervention groups between June 2013 and October 2014. Analyses were conducted from August 2017 to June 2018. INTERVENTIONS: Abiraterone acetate, 1000 mg, once daily with prednisone, 5 mg, twice daily (n = 41), 5 mg once daily (n = 41), 2.5 mg twice daily (n = 40), or dexamethasone, 0.5 mg, once daily (n = 42). MAIN OUTCOMES AND MEASURES: Primary end point was no mineralocorticoid excess (grade ≥1 hypokalemia or grade ≥2 hypertension) through 24 weeks (6 cycles) from treatment. RESULTS: Of 164 men (median [range] age, 70 [50-90] years) randomized to receive abiraterone acetate, 1000 mg, daily with prednisone, 5 mg, twice daily, once daily, or 2.5 mg twice daily, or dexamethasone, 0.5 mg, once daily, 24 (70.6%) of 34 patients (95% CI, 53.8%-83.2%), 14 (36.8%) of 38 patients (95% CI, 23.4%-52.7%), 21 (60.0%) of 35 patients (95% CI, 43.6%-74.4%), and 26 (70.3%) of 37 patients (95% CI, 54.2%-82.5%), respectively, had no mineralocorticoid excess. Plasma adrenocorticotrophic hormone and urinary mineralocorticoid metabolites after 8 weeks were higher with prednisone, 2.5 mg, twice daily and 5 mg once daily than with 5 mg twice daily or dexamethasone, 0.5 mg, once daily. The level of urinary glucocorticoid metabolites appeared higher in patients who did not meet the primary end point, regardless of glucocorticoid regimen. Total lean body mass decreased in the prednisone groups and total body fat increased in the prednisone, 5 mg, twice daily and dexamethasone groups. In the dexamethasone group, there was an increase in serum insulin and homeostatic model assessment of insulin resistance, while total bone mineral density decreased. In the prednisone, 5 mg, twice daily, 5 mg once daily, 2.5 mg twice daily, and dexamethasone groups, median radiographic progression-free survival was 18.5, 15.3, 12.8, and 26.6 months, respectively. CONCLUSIONS AND RELEVANCE: Abiraterone acetate with prednisone, 5 mg, twice daily or dexamethasone, 0.5 mg, once daily met the prespecified threshold for the primary end point (95% CI excluded 50% mineralocorticoid excess); abiraterone acetate with prednisone, 5 mg, once daily or 2.5 mg twice daily did not meet the threshold. Abiraterone acetate in combination with dexamethasone appeared to be particularly active but may be associated with adverse metabolic consequences. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01867710.

Published
2019

36. Long-Term Outcomes and Genetic Predictors of Response to Metastasis Directed Therapy vs. Observation in Oligometastatic Castration-Sensitive Prostate Cancer: A Pooled Analysis of the STOMP and ORIOLE Trials

Author

Deek, M.P., Van der Eecken, K., Sutera, P., Deek, R., Fonteyne, V., Amaral, A., Lumen, N., Phillips, R., Delrue, L., Verbeke, S., De Man, K., Song, D., Paller, C., Joniau, S., De Meerleer, G., Lotan, T.L., Berlin, A., Siva, S., Ost, P., and Tran, P.T.

Published
2022
Full Text
View/download PDF

37. SC275 - The risk of recurrence in cN1 prostate cancer patients treated with radical prostatectomy varies according to the type preoperative staging. a comparison between 68ga-PSMA-PET versus conventional imaging in a large, multi-institutional study

Author

Sorce, G., Rosiello, G., Gandaglia, G., Scuderi, S., Bianchi, L., Schiavina, R., Vansevenant, B., Devos, G., Stabile, A., Leni, R., Robesti, D., Mazzone, E., Pellegrino, A., Scilipoti, P., Fossati, N., D’Ambrosio, L., Gallina, A., Picozzi, M., Tutolo, M., Martini, A., Joniau, S., Karnes, R.J., Montorsi, F., and Briganti, A.

Published
2022
Full Text
View/download PDF

38. SC274 - How to optimize patient selection before salvage lymph node dissection for nodal recurrent prostate cancer: a novel risk stratification tool

Author

Cannoletta, D., Fossati, N., Karnes, R.J., Heidenreich, A., Kretschmer, A., Stief, C., Joniau, S., Van Poppel, H., Osmonov, D., Juenemann, K., Shariat, S., Hiester, A., Albers, P., Tilki, D., Graefen, M., Gill, I.S., Scilipoti, P., Mazzone, E., Stabile, A., Mottrie, A., Gandaglia, G., Gallina, A., Montorsi, F., and Briganti, A.

Published
2022
Full Text
View/download PDF

39. SC239 - Who is the right patient for salvage radical prostatectomy? oncological outcomes compared between EAU guidelines-compliant and non-compliant patients

Author

Calleris, G., Marra, G., Gontero, P., Van Der Poel, H., Veerman, H., Cathcart, P., Ribiero, L., Valerio, M., Gandaglia, G., Albisinni, S., Kretschmer, A., Westhofen, T., Gill, I., Abreu, A., Cacciamani, G., Ghoreifi, A., Aron, M., Berger, A., Joniau, S., Raskin, Y., Persad, R., Tilki, D., Smith, J., Sanchez-Salas, R., Barbosa, R. Tourinho, Ahmed, M., Morlacco, A., Karnes, R.J., Shariat, S., and Pawel, R.

Published
2022
Full Text
View/download PDF

40. SC208 - What is the optimal management of nodal oligorecurrent prostate cancer? results from a large series of patients treated with salvage lymph node dissection

Author

Fossati, N., Karnes, R.J., Heidenreich, A., Kretschmer, A., Buchner, A., Stief, C., Joniau, S., Van Poppel, H., Osmonov, D., Jueneman, K., Shariat, S., Hiester, A., Albers, P., Tilki, D., Graefen, M., Gill, I.S., Mottrie, A., Gandaglia, G., Gallina, A., Montorsi, F., and Briganti, A.

Published
2022
Full Text
View/download PDF

41. SC93 - Development and validation of a novel nomogram predicting long-term progression in patients treated with early salvage radiation therapy after radical prostatectomy: the key role of PSA kinetics

Author

Scilipoti, P., Fossati, N., Mazzone, E., Karnes, J.R., Boorjian, S.A., Motterle, G., Bossi, A., Kumar, T., Di Muzio, N., Cozzarini, C., Chiorda, B. Noris, Robesti, D., Cirulli, G., Gandaglia, G., Suardi, N., Bartkowiak, D., Shariat, S., Goldner, G., Berghen, C., Joniau, S., Stabile, A., Cucchiara, V., van Poppel, H., De Meerleer, G., Karakiewicz, P., Wiegel, T., Montorsi, F., and Briganti, A.

Published
2022
Full Text
View/download PDF

42. SC94 - Toxicity profile of immediate post-prostatectomy radiation therapy: results from a large multi-institutional series

Author

Cannoletta, D., Fossati, N., Karnes, R.J., Boorjan, S.A., Bossi, A., Di Muzio, N., Cozzarini, C., Chiorda, B. Noris, Gandaglia, G., Bartkowiak, D., Shariat, S., Goldner, G., Berghen, C., Joniau, S., De Meerleer, G., Scilipoti, P., Mazzone, E., Stabile, A., van Poppel, H., Gallina, A., Wiegel, T., Montorsi, F., and Briganti, A.

Published
2022
Full Text
View/download PDF

43. SC1 - Oncological outcomes, patterns of recurrence and impact of competing causes of mortality in clinically node-positive prostate cancer patients treated with radical prostatectomy

Author

Cirulli, G., Gandaglia, G., Robesti, D., Karnes, J.R., Devos, G., Berghen, C., Evaraerts, W., Joniau, S., Pellegrino, A., De Angelis, M., van Poppel, H., Stabile, A., Gallina, A., Cucchiara, V., Tutolo, M., Mazzone, E., Rosiello, G., Leni, R., Fossati, N., Dehò, F., Montorsi, F., and Briganti, A.

Published
2022
Full Text
View/download PDF

44. 1381P A transcriptomic signature of AR activity prognosticates development of castration-resistance following metastasis-directed therapy in oligometastatic castration-sensitive prostate cancer

Author

Tran, P.T., Sutera, P., Deek, M., Van der Eecken, K., Hakansson, A., Liu, S., Chang, J., Fonteyne, V., Mendes, A., Lumen, N., Delrue, L., Verbeke, S., De Man, K., Song, D.Y., Paller, C., Davicioni, E., Joniau, S., De Meerleer, G., Lotan, T., and Ost, P.

Published
2022
Full Text
View/download PDF

45. PT079 - Which patients should be still considered for late salvage radiotherapy for rising or persistently elevated PSA after radical prostatectomy: Results from a large multi-institutional study

Author

Noris Chiorda, B., Fossati, N., Karnes, J., Soligo, M., Boorjian, S., Bossi, A., Coraggio, G., Di Muzio, N., Cozzarini, C., Fiorino, C., Gandaglia, G., Robesti, D., Bartkowiak, D., Budach, V., Shariat, S., Goldner, G., Battaglia, A., Joniau, S., Haustermans, K., De Meerleer, G., Fonteyne, V., Ost, P., Van Poppel, H., Montorsi, F., Wiegel, T., and Briganti, A.

Published
2018
Full Text
View/download PDF

47. A0825 - Oncological outcomes, patterns of recurrence and impact of competing causes of mortality in clinically node-positive prostate cancer patients treated with radical prostatectomy

Author

Cirulli, G.O., Robesti, D., Gandaglia, G., Cucchiara, V., Karnes, R.J., Devos, G., Berghen, C., Evaraerts, W., Joniau, S., Pellegrino, A., Rosiello, G., Leni, R., Tutolo, M., De Angelis, M., Gallina, A., Fossati, N., Dehò, F., Van Poppel, H., Montorsi, F., and Briganti, A.

Published
2022
Full Text
View/download PDF

48. A0826 - The risk of recurrence in cN1 prostate cancer patients treated with radical prostatectomy varies according to preoperative staging. A comparison between 68Ga-PSMA-PET versus conventional imaging in a large, multi-institutional study

Author

Sorce, G., Rosiello, G., Gandaglia, G., Stabile, A., Robesti, D., Scuderi, S., Mazzone, E., Pellegrino, A., Martini, A., Leni, R., Dambrosio, L., Picozzi, M., Tutolo, M., Gallina, A., Fossati, N., Bianchi, L., Schiavina, R., Vansevenant, B., Devos, G., Karnes, J., Joniau, S., Montorsi, F., and Briganti, A.

Published
2022
Full Text
View/download PDF

50. Recurrence, progression and cancer-specific mortality according to stage at re-TUR in T1G3 bladder cancer patients treated with BCG: not as bad as previously thought

Author

Palou, J. Pisano, F. Sylvester, R. Joniau, S. Serretta, V. Larré, S. Di Stasi, S. van Rhijn, B. Witjes, A.J. Grotenhuis, A. Colombo, R. Briganti, A. Babjuk, M. Soukup, V. Malmstrom, P.U. Irani, J. Malats, N. Baniel, J. Mano, R. Cai, T. Cha, E.K. Ardelt, P. Varkarakis, J. Bartoletti, R. Dalbagni, G. Shariat, S.F. Xylinas, E. Karnes, R.J. Gontero, P.

Abstract

Purpose: The goals of transurethral resection of a bladder tumor (TUR) are to completely resect the lesions and to make a correct diagnosis to adequately stage and treat the patient. Persistent disease after TUR is not uncommon and is why re-TUR is recommended in T1G3 patients. When there is T1 tumor in the re-TUR specimen, very high risks of progression (82%) have been reported. We analyze the risks of recurrence, progression to muscle-invasive disease and cancer-specific mortality (CSM) according to tumor stage at re-TUR in T1G3 patients treated with BCG. Methods: In our retrospective cohort of 2451 T1G3 patients, 934 patients (38.1%) underwent re-TUR. 667 patients had residual disease (71.4%): Ta in 378 (40.5%), T1 in 289 (30.9%) patients. Times to recurrence, progression and CSM in the three groups were estimated using cumulative incidence functions and compared using the Cox regression model. Results: During a median follow-up of 5.2 years, 512 patients recurred. The recurrence rate was significantly higher in patients with a T1 at re-TUR (P < 0.001). Progression rates differed according to the pathology at re-TUR, 25.3% in T1, 14.6% in Ta and 14.2% in case of no residual tumor (P < 0.001). Similar trends were seen in both patients with and without muscle in the original TUR specimen. Conclusions: Patients with T1G3 tumors and no residual disease or Ta at re-TUR have better recurrence, progression and CSM rates than previously reported, with a CSM rate of 13.1 and a 25.3% progression rate in re-TUR T1 disease. © 2018, Springer-Verlag GmbH Germany, part of Springer Nature.

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results